Isavuconazonium sulfate for the treatment of fungal infection

R C Walker1, J D Zeuli2, Z Temesgen3

  • 1Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.

Insights

Isavuconazole is a new antifungal medication approved for invasive aspergillosis and mucormycosis. It offers broad-spectrum coverage and a favorable safety profile compared to older azoles.

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Invasive fungal infections (IFIs) pose significant clinical challenges.
  • Azole antifungals are crucial for treating IFIs.
  • Newer agents are needed to address resistance and improve safety profiles.

Purpose of the Study:

  • To review the current status and potential applications of isavuconazole.
  • To highlight its efficacy in treating invasive aspergillosis and invasive mucormycosis.
  • To compare its safety and drug interaction profile with voriconazole.

Main Methods:

  • Review of clinical trial data and post-marketing surveillance.
  • Pharmacokinetic and pharmacodynamic analyses.
  • Comparative studies with existing antifungal therapies.

Main Results:

  • Isavuconazole demonstrates broad-spectrum activity against yeasts, molds, and dimorphic fungi.
  • Isavuconazonium sulfate is approved for invasive aspergillosis and mucormycosis.
  • Favorable safety and lower drug interaction potential compared to voriconazole.

Conclusions:

  • Isavuconazole is a valuable therapeutic option for specific IFIs.
  • Further research is needed to explore its role in other fungal infections and prophylaxis.
  • Its utility in azole-experienced patients requires further clinical investigation.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
29
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.0K
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
847
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.0K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
605
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.2K